Chia-Sheng Huang

Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan

Mei-Hsuan Lee, J. Kao, Chun-Jen Liu, 2021, Infectious Diseases and Therapy.

Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals

J. Kao, Chia-Chi Wang, Han‐Chieh Lin, 2022, Viruses.

Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan

J. Kao, Chun-Jen Liu, C. Hung, 2021, Hepatology International.

Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment

J. Kao, Chun-Jen Liu, Chun-Chao Chang, 2021, Gut.

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis

J. Kao, Chun-Jen Liu, Chun-Chao Chang, 2021, Clinical and molecular hepatology.

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan

J. Kao, Chun-Jen Liu, Chia-Chi Wang, 2021, Scientific Reports.

Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: a large cohort study from the nationwide HCV Registry Program (TACR).

J. Kao, Chun-Jen Liu, Chia-Chi Wang, 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.

J. Kao, Chun-Jen Liu, Chia-Chi Wang, 2022, Journal of the Formosan Medical Association = Taiwan yi zhi.

Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

J. Kao, Chun-Jen Liu, Y. Shih, 2023, Hepatology International.